Ticagrelor Reduces Thromboinflammatory Markers in Patients With Pneumonia

Travis R. Sexton, Guoying Zhang, Tracy E. Macaulay, Leigh A. Callahan, Richard Charnigo, Olga A. Vsevolozhskaya, Zhenyu Li, Susan Smyth

Research output: Contribution to journalArticlepeer-review

99 Scopus citations


Despite treatment advances for sepsis and pneumonia, significant improvements in outcome have not been realized. Antiplatelet therapy may improve outcome in pneumonia and sepsis. In this study, the authors show that ticagrelor reduced leukocytes with attached platelets as well as the inflammatory biomarker interleukin (IL)-6. Pneumonia patients receiving ticagrelor required less supplemental oxygen and lung function tests trended toward improvement. Disruption of the P2Y12 receptor in a murine model protected against inflammatory response, lung permeability, and mortality. Results indicate a mechanistic link between platelets, leukocytes, and lung injury in settings of pneumonia and sepsis, and suggest possible therapeutic approaches to reduce complications.(Targeting

Original languageEnglish
Pages (from-to)435-449
Number of pages15
JournalJACC: Basic to Translational Science
Issue number4
StatePublished - Aug 2018

Bibliographical note

Publisher Copyright:
© 2018


  • inflammation
  • leukocytes
  • platelets
  • pneumonia
  • sepsis

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Ticagrelor Reduces Thromboinflammatory Markers in Patients With Pneumonia'. Together they form a unique fingerprint.

Cite this